OM:BIOVIC B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Biovica International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIOVIC B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.4%

BIOVIC B

7.7%

SE Biotechs

2.8%

SE Market


1 Year Return

194.6%

BIOVIC B

43.9%

SE Biotechs

17.5%

SE Market

Return vs Industry: BIOVIC B exceeded the Swedish Biotechs industry which returned 43.9% over the past year.

Return vs Market: BIOVIC B exceeded the Swedish Market which returned 17.5% over the past year.


Shareholder returns

BIOVIC BIndustryMarket
7 Day15.4%7.7%2.8%
30 Day26.4%10.9%5.5%
90 Day70.2%19.0%13.8%
1 Year194.6%194.6%45.2%43.9%19.6%17.5%
3 Year166.0%166.0%62.5%58.3%37.9%23.2%
5 Yearn/a106.4%93.4%74.3%40.2%

Price Volatility Vs. Market

How volatile is Biovica International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biovica International undervalued compared to its fair value and its price relative to the market?

15.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIOVIC B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BIOVIC B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BIOVIC B is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.

PE vs Market: BIOVIC B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOVIC B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIOVIC B is overvalued based on its PB Ratio (15.5x) compared to the SE Biotechs industry average (6.1x).


Next Steps

Future Growth

How is Biovica International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

29.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOVIC B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOVIC B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOVIC B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOVIC B's revenue (58.6% per year) is forecast to grow faster than the Swedish market (3.8% per year).

High Growth Revenue: BIOVIC B's revenue (58.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOVIC B's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biovica International performed over the past 5 years?

-28.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIOVIC B is currently unprofitable.

Growing Profit Margin: BIOVIC B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOVIC B is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.

Accelerating Growth: Unable to compare BIOVIC B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOVIC B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: BIOVIC B has a negative Return on Equity (-46.64%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biovica International's financial position?


Financial Position Analysis

Short Term Liabilities: BIOVIC B's short term assets (SEK32.5M) exceed its short term liabilities (SEK8.8M).

Long Term Liabilities: BIOVIC B's short term assets (SEK32.5M) exceed its long term liabilities (SEK2.4M).


Debt to Equity History and Analysis

Debt Level: BIOVIC B is debt free.

Reducing Debt: BIOVIC B has no debt compared to 5 years ago when its debt to equity ratio was 0.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOVIC B has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BIOVIC B is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Biovica International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOVIC B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOVIC B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOVIC B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOVIC B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIOVIC B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Anders Rylander (50 yo)

10.67yrs

Tenure

Mr. Anders Rylander serves as Chief Executive Officer of Biovica International AB (publ) since 2010. Mr. Rylander is the Founder of Arinvest and Co-Founder of Axholmen. He has been a Management Consultant ...


Leadership Team

NamePositionTenureCompensationOwnership
Anders Rylander
CEO & Director10.67yrsno data13.99%
SEK 151.5m
Jarl Jungnelius
Director & Senior Oncology Advisor6.67yrskr150.00kno data
Cecilia Driving
Chief Financial Officer3.67yrsno data0.035%
SEK 383.0k
Adam Germunder
Operations Director2.75yrsno data0.016%
SEK 176.2k
Robert Dann
Senior Vice President of Marketing & US Business0.42yrno data0.071%
SEK 766.0k
Henrik Winther
Senior Vice President of Business Development0.75yrno datano data
Otti Gref
R&D Directorno datano datano data
Mattias Bergqvist
Vice President of Clinical Developmentno datano datano data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: BIOVIC B's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anders Rylander
CEO & Director10.67yrsno data13.99%
SEK 151.5m
Jarl Jungnelius
Director & Senior Oncology Advisor6.67yrskr150.00kno data
Lars Holmqvist
Chairman of the Board1.5yrskr400.00k1.63%
SEK 17.6m
Annika Berg
Director0.67yrno datano data
Maria Holmlund
Director4.67yrskr150.00k0.034%
SEK 373.4k
Jesper Söderqvist
Director7.67yrskr150.00k0.29%
SEK 3.2m
Marie-Louise Fjallskog
Director0.67yrno datano data
Henrik Osvald
Director1.08yrskr150.00k1.68%
SEK 18.2m

3.1yrs

Average Tenure

59yo

Average Age

Experienced Board: BIOVIC B's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BIOVIC B insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.


Top Shareholders

Company Information

Biovica International AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biovica International AB (publ)
  • Ticker: BIOVIC B
  • Exchange: OM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr1.083b
  • Shares outstanding: 28.27m
  • Website: https://www.biovica.com

Number of Employees


Location

  • Biovica International AB (publ)
  • Dag Hammarskjölds väg 54B
  • Uppsala Science Park
  • Uppsala
  • Uppsala County
  • 752 37
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOVIC BOM (OMX Nordic Exchange Stockholm)YesB SharesSESEKMar 2017

Biography

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 03:25
End of Day Share Price2020/09/18 00:00
Earnings2020/07/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.